Hepatitis C virus (HCV) is a blood-borne infection that can cause progressive liver damage if it remains untreated. Modern direct-acting antiviral (DAA) medicines have transformed hepatitis C treatment, with oral treatment courses commonly lasting 8–12 weeks and curing most infections. The NHS states that hepatitis C treatment can cure infection in most people and that patients are generally monitored with blood tests during and after treatment.
For UK healthcare buyers, understanding the role of Sofosbuvir 400 mg, its approved combinations, treatment considerations and sourcing requirements is important when evaluating pharmaceutical supply options.
What Is Sofosbuvir 400 mg?
Sofosbuvir is a nucleotide analogue inhibitor that targets the HCV NS5B RNA-dependent RNA polymerase, an enzyme required for viral replication. It is used as part of DAA treatment regimens for chronic hepatitis C rather than generally being considered as a standalone treatment. NICE guidance describes sofosbuvir as an established component of treatment for specific chronic HCV populations.
The 400 mg strength is particularly important in commonly used fixed-dose combinations. For example, UK-authorised sofosbuvir/velpatasvir contains 400 mg of sofosbuvir with 100 mg of velpatasvir per tablet. NICE describes this combination as an oral treatment for chronic hepatitis C across HCV genotypes 1–6 within its licensed use.
Sofosbuvir 400 mg in Hepatitis C Treatment
The appropriate HCV regimen depends on factors such as genotype, liver disease or cirrhosis status, previous treatment history, drug interactions and other clinical considerations.
For example, the UK Summary of Product Characteristics for sofosbuvir/velpatasvir states that adults generally take one 400 mg/100 mg tablet once daily. For adults without cirrhosis or with compensated cirrhosis, the listed treatment duration is 12 weeks; treatment requirements can differ for patients with decompensated cirrhosis.
Healthcare professionals should therefore select treatment according to the patient's clinical circumstances and current UK prescribing guidance rather than treating the 400 mg strength as a universal regimen.
Information for UK Pharmaceutical Buyers
UK hospitals, pharmacies, wholesalers, distributors and healthcare procurement organisations considering Sofosbuvir 400 mg supply from India should assess several factors before purchasing.
These include:
- Product strength and formulation
- Manufacturer and product documentation
- Batch and expiry information
- Packaging and labelling
- Certificate of Analysis (CoA), where applicable
- Regulatory and import requirements
- Storage and transportation conditions
- Supplier quality-assurance procedures
- Documentation required for UK pharmaceutical procurement
Buyers should also distinguish between Sofosbuvir 400 mg alone and combination products such as sofosbuvir/velpatasvir or ledipasvir/sofosbuvir, because their compositions, indications and regulatory requirements are different. The UK medicines information for sofosbuvir/velpatasvir confirms that the product contains 400 mg sofosbuvir plus 100 mg velpatasvir.
Why Choose an Indian Pharmaceutical Exporter?
India has an established pharmaceutical manufacturing and export sector, making Indian suppliers a potential sourcing option for international healthcare buyers. For UK buyers, however, product quality, regulatory compliance, documentation and lawful importation should remain central considerations when evaluating an overseas supplier.
Global Pharma Trade can provide product and export information for healthcare buyers interested in Sofosbuvir 400 mg from India, including available formulations, packaging, documentation and quotation requirements. Buyers should provide their required quantity and destination details so that applicable supply and import requirements can be assessed.
Frequently Asked Questions
Is Sofosbuvir 400 mg used for hepatitis C?
Yes. Sofosbuvir 400 mg is an established antiviral component of hepatitis C treatment regimens. Its use depends on the specific treatment combination and patient's clinical circumstances.
How long does hepatitis C treatment take in the UK?
The NHS states that hepatitis C is commonly treated with antiviral tablets for 8 to 12 weeks, although the exact regimen and duration depend on individual clinical factors.
Can UK healthcare buyers source Sofosbuvir 400 mg from India?
Healthcare buyers may explore pharmaceutical supply from India, subject to applicable UK import, regulatory, procurement and quality requirements.
Is Sofosbuvir 400 mg suitable for every hepatitis C patient?
No. Treatment selection depends on factors including HCV genotype, liver disease status, previous treatment and potential drug interactions. A qualified healthcare professional should determine the appropriate regimen.
Conclusion: Sofosbuvir 400 mg remains an important component of modern hepatitis C treatment. For UK healthcare buyers, evaluating the correct formulation, supplier documentation, quality standards and regulatory requirements is essential when sourcing from India.
